PAVmed Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

PAVmed hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	1.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$7.53
Erwartete Dividendenrendite in 3 Jahren	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress

Jul 05

Start Accumulating PAVmed

Dec 24

We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth

Sep 02

PAVmed: Long Term Investment Case Remains Despite Weak Q2

Aug 23

PAVmed: A True Game-Changer For Medical Device Innovation

Jun 14

PAVmed forms digital health company, Veris Health

Jun 02

PAVmed's subsidiary receives CE mark for EsoCheck esophageal cell collection device

May 26

PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans

May 19

PAVmed drops 14% on launch of $13.4M direct offering

Jan 06

PAVmed closes additional direct offering of common stock

Dec 22

Do Institutions Own PAVmed Inc. (NASDAQ:PAVM) Shares?

Dec 16

PAVmed offers stock for $8.9M

Dec 11

PAVmed EPS beats by $0.02

Nov 17

There Is Progress At PAVmed, But More Patience Is Required

Oct 30

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von PAVM in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von PAVM gestiegen sind.

Dividendenrendite im Vergleich zum Markt

PAVmed Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von PAVM im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (PAVM)	n/a
Untere 25 % des Marktes (US)	1.5%
Markt Top 25 % (US)	4.7%
Branchendurchschnitt (Medical Equipment)	1.8%
Analystenprognose in 3 Jahren (PAVM)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von PAVM im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von PAVM im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von PAVM, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da PAVM keine Ausschüttungen gemeldet hat.

PAVmed Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Lucid Diagnostics Announces Positive Data from Its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of Esoguard Esophageal Precancer Testing in A Screening Population

Insufficient new directors

New major risk - Market cap size

Consensus EPS estimates fall by 13%, revenue upgraded

Price target decreased by 21% to US$13.00

Pavmed Inc. Appoints Dennis Matheis to Board of Directors

PAVmed Inc., Annual General Meeting, Jun 20, 2024

Consensus revenue estimates decrease by 28%, EPS upgraded

Price target decreased by 21% to US$16.38

Full year 2023 earnings: EPS exceeds analyst expectations

PAVmed Inc. Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX

PAVmed Receives Notice from Nasdaq Regarding Non-Compliance with the Market Value of the Company’s Listed Securities Under Nasdaq Listing Rule 5550(b)(2)

New major risk - Share price stability

Are Investors Undervaluing PAVmed Inc. (NASDAQ:PAVM) By 28%?

Now 24% undervalued after recent price drop

Lucid Diagnostics Inc. and Pavmed Inc. Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies

Price target decreased by 48% to US$20.63

Pavmed Inc. Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Pre Cancer Detection

Consensus revenue estimates decrease by 12%

New major risk - Negative shareholders equity

PAVmed Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Consensus revenue estimates increase by 35%

Consensus revenue estimates decrease by 40%, EPS upgraded

Consensus revenue estimates increase by 33%

No longer forecast to breakeven

PAVmed Receives A Notice from Nasdaq Regarding Minimum Bid Price Requirement

Independent Vice Chairman recently bought US$161k worth of stock

Price target decreased to US$5.06

Consensus forecasts updated

Consensus forecasts updated

Consensus revenue estimates fall by 80%

Price target decreased to US$5.50

Is PAVmed (NASDAQ:PAVM) Using Debt In A Risky Way?

PAVmed Non-GAAP EPS of -$0.17 beats by $0.03

PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress

PAVmed Inc.(NasdaqCM:PAVM) dropped from Russell 2000 Dynamic Index

PAVmed Inc., Annual General Meeting, Jun 21, 2022

PAVmed Inc. announced delayed annual 10-K filing

Consensus revenue estimates fall by 10%

Price target decreased to US$8.13

PAVmed Inc. Appoints Shaun O’Neil as Executive Vice President and Chief Operating Officer

PAVmed Inc. Appoints Joan Harvey to Its Board of Directors

Start Accumulating PAVmed

Consensus forecasts updated

Price target increased to US$9.50

We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth

PAVmed: Long Term Investment Case Remains Despite Weak Q2

Consensus revenue estimates fall to US$1.02m

Independent Director David Battleman has left the company

Independent Director David Weild has left the company

PAVmed: A True Game-Changer For Medical Device Innovation

Consensus forecasts updated

PAVmed forms digital health company, Veris Health

PAVmed's subsidiary receives CE mark for EsoCheck esophageal cell collection device

Data Presented at Digestive Disease Week 2021 Support Clinical Utility of PAVmed Subsidiary Lucid Diagnostics’ EsoCheck and EsoGuard Technologies

PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans

Consensus forecasts updated

PAVmed Inc. has completed a Follow-on Equity Offering in the amount of $41.576088 million.

Price target raised to US$6.42

First U.S. Patient Undergoes Successful Minimally Invasive Carpal Tunnel Release Using PAVmed’s CarpX® Device

New 90-day high: US$2.68

PAVmed Inc. has completed a Follow-on Equity Offering in the amount of $13.44 million.

PAVmed drops 14% on launch of $13.4M direct offering

New 90-day high: US$2.13

PAVmed Inc. has completed a Follow-on Equity Offering in the amount of $8.1 million.

PAVmed closes additional direct offering of common stock

Do Institutions Own PAVmed Inc. (NASDAQ:PAVM) Shares?

PAVmed offers stock for $8.9M

New 90-day high: US$2.06

PAVmed EPS beats by $0.02

New 90-day low: US$1.73

There Is Progress At PAVmed, But More Patience Is Required

New 90-day low: US$1.76

New 90-day low - US$1.80

New 90-day low - US$1.93